ESMO 2026 Day 3: Top Trials and KOL Reactions
ESMO 2026 Day 3: KRASCENDO-1 and the crossover question, SAFFRON, HARMONi-GI1, CLARITY-Gastric01, PERSEE, LITESPARK-012, NADINA and more, with physician reactio…
ESMO 2026: Top Breast Cancer Trials and KOL Voices
ESMO 2026 Madrid breast cancer, October 23–26: NATALEE, KEYNOTE-B49, PANKU-Breast01, FOURLIGHT-1, SWITCH, BRIDGET, OptiTROP-Breast01 and DESTINY-Breast09, with …
ESMO 2026 Days 1–2: Top Trials and KOL Reactions
ESMO 2026 Days 1-2: a standing ovation for DeLLphi-305 and the crossover question physicians raised, plus INTerpath-001, VOLGA, NATALEE, PANKU-Breast01 and more…
The ESMO 2026 Debates from the KOL Social Media Threads
ESMO 2026 physician debates on X, verbatim: INTerpath-001 vs neoadjuvant IO, NATALEE's nominal OS p-value, me-too HER2 ADCs, pCR vs EFS in bladder cancer, KEYNO…
PATINA Trial - Dr. Olivier Told You So!!!
Feb: Timothée Olivier, MD, flagged PATINA's open-label, investigator-assessed PFS. Jun: FDA approval. Oct: EMA says benefits “had not been demonstrated.”
Etcamah (Camizestrant) Is FDA Approved — and Some KOLs Still Agree With ODAC's No Vote
SERENA-6 KOL sentiment after the Etcamah (camizestrant) FDA approval: Tatiana Prowell, Angela DeMichele's ASCO plenary takeaways, Gyawali and other voices who s…
Gedatolisib (Revtorpyk) Is FDA Approved: What Breast Oncology KOLs Said on Day One
What breast oncology KOLs said within hours of the gedatolisib (Revtorpyk) FDA approval: doublet vs triplet, weekly-IV burden, and the 2.0-month control arm.
Dr. Vinay Prasad's Views on Key ASCO Breast Cancer Trials
Dr. Vinay Prasad is now Director of FDA's CBER Division, Review his thoughts on NATALEE, DESTINY-Breast04, and postMONARCH breast cancer clinical trials
DESTINY-Breast09 is Trending, What About PATINA?
Breast Cancer experts from the global KOL community have been buzzing about DESTINY-Breast09 and PATINA clinical trials. Track their social media insights.